Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha-Reference-Cited by-同舟云学术

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

Published:1992-01 Issue:1 Volume:28 Page:92-96
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lissoni P.,Barni S.,Ardizzoia A.,Crispino S.,Paolorossi F.,Archili C.,Vaghi M.,Tancini G.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer;Rosenberg;N Engl J Med,1985

2. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer;West;N Engl J Med,1987

3. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone;Rosenberg;N Engl J Med,1987

4. Interleukin-2 with or without LAK cells in metastatic renal cancer cell carcinoma: a report of a European Multicentre Study;Negrier;Eur J Cancer,1989

5. Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies;Atzpodien;Lancet,1990

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Principles of psychoneuroendocrinoimmunotherapy of cancer;Immunotherapy;2012-01

2. How Can Second-Line Therapy for Metastatic Renal Cell Carcinoma Help to Define an Overall Management Strategy?;Oncology;2009

3. Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results;Renal Cell Carcinoma;2009

4. Systemic Therapy for Metastatic Renal Cell Carcinoma: Cytokines;Clinical Management of Renal Tumors;2008

5. Synergy of Interferon-α and 5-Fluorouracil in Human Renal Cell Carcinoma Requires p53 Activity;European Urology;2007-10